Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CHD stock price vs PFE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PFE's multiple
Needs PFE P/E.
Implied fair value · at CHD's multiple
Needs CHD P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CHURCH & DWIGHT CO., INC. · implied price per share
Bear
$37.82
Base
$45.81
Bull
$56.21
PFIZER INC · implied price per share
Bear
$10.17
Base
$12.82
Bull
$17.53
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CHD vs PG
COLGATE PALMOLIVE CO
CHD vs CL
KIMBERLY CLARK CORP
CHD vs KMB
ESTEE LAUDER COMPANIES INC
CHD vs EL
JOHNSON & JOHNSON
CHD vs JNJ
Merck & Co., Inc.
CHD vs MRK
AbbVie Inc.
CHD vs ABBV
BRISTOL MYERS SQUIBB CO
CHD vs BMY
ELI LILLY & Co
CHD vs LLY
AMGEN INC
CHD vs AMGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CHD can sustain a premium multiple despite only modest growth and margin advantages, then avoid chasing the stock at current levels because PFE-implied valuation points to -41.2% downside and both P/E and P/S remain well above PFE.
CHD's current price of $97.03 implies a downside to $57.07, or -41.2%, versus PFE-based valuation, indicating a large relative valuation gap. The discount is driven by CHD's much richer multiples than PFE across P/E, P/S, EV/EBITDA, and EV/Revenue despite only modestly better growth and leverage metrics.
Supporting Metrics
